Piper Sandler Reiterates Overweight Rating on Turnstone Biologics (TSBX)

May 24, 2024 7:31 AM EDT Send to a Friend
Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $20.00 price target on Turnstone Biologics (NASDAQ: TSBX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login